Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Core Insights - Vor Bio has appointed Han Choi, M.D., LL.M., as the new Chief Financial Officer, effective immediately [1][3] - Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy within the pharmaceutical and biotechnology sectors [2][3] - The company aims to transform treatment outcomes for patients with acute myeloid leukemia (AML) and other blood cancers through innovative cell and genome engineering [4] Company Overview - Vor Bio is a clinical-stage company focused on cell and genome engineering, specifically targeting blood cancers by engineering hematopoietic stem cells for post-transplant therapies [4] - The company is advancing its clinical pipeline and expanding its leadership in the field [2] Leadership Background - Dr. Choi previously served as a Principal at Oracle Investment Management, specializing in healthcare investments, where he managed investments in the pharmaceutical and biotechnology sectors [3] - He has held significant roles in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company [3] Compensation Details - As part of his appointment, Dr. Choi was granted stock options to purchase 400,000 shares of Vor Bio's common stock [5] - The stock options have a ten-year term with an exercise price equal to the closing price on September 30, 2024, and will vest over four years [6]